Public procurement notice: Contract Award Notice
Published: 2020-08-19
Buyer: The NHS Commissioning Board (operating under the name of NHS England)
Country: UK
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products
Estimated value: 590125406 GBP
Award criteria: The most economic tender

Technical requirements: NHS Framework for the NHS London Region, Branded Medicines — Tranche A plus Cytokine Modulators and Other Products and Dolutegravir/Lamivudine
NHS framework for the NHS London Region, Branded Medicines — Tranche A, Annual Tranche — Cytokine Modulators and other products and Dolutegravir/Lamivudine.
CM/PHR/16/5516/01 — London Tranche A — 1 September 2020 to 31 August 2022 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
CM/PHR/16/5516/02 — London Annual Tranche — Cytokine Modulators and other products — 1 September 2020 to 31 August 2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.
CM/PHR/16/5516/03 — NHS framework agreement for the supply of Dolutegravir/Lamivudine — North of England — 1 September 2020-28 February 2021, South of England — 1 September 2020-31 August 2021, Midlands and East — 1 September 2020-28 February 2022, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
CM/PHR/16/5516/01 — London Tranche A — 1 September 2020 to 31 August 2022 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
Each individual national product code (NPC) pack description in each of the regions is deemed to be a separate product for the application of the award criteria.
The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.
The framework may also be used by private sector contractors and agents working on behalf of the above.
CM/PHR/16/5516/02 — London Annual Tranche — Cytokine Modulators and other products — 1 September 2020 to 31 August 2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.
Each individual national product code (NPC) pack description in each of the regions is deemed to be a separate product for the application of the award criteria.
The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.
The framework may also be used by private sector contractors and agents working on behalf of the above.
CM/PHR/16/5516/03 — NHS Framework agreement for the supply of Dolutegravir/Lamivudine — North of England — 1 September 2020-28 February 2021, South of England — 1 September 2020-31 August 2021, Midlands and East — 1 September 2020-28 February 2022, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
Each individual national product code (NPC) pack description in each of the regions is deemed to be a separate product for the application of the award criteria.


Winner: AbbVie Ltd
Award value: 590125406
Number of bids: 28